Portal:RareDisease/FeaturedPathways
From WikiPathways
(Difference between revisions)
Current revision (11:39, 2 June 2021) (view source) |
|||
| (15 intermediate revisions not shown.) | |||
| Line 22: | Line 22: | ||
|width=100px|{{#pwImage:Pathway:WP4746|250px||Thyroid hormones production and their peripheral downstream signalling effects regarding congenital hypothyroidism}} | |width=100px|{{#pwImage:Pathway:WP4746|250px||Thyroid hormones production and their peripheral downstream signalling effects regarding congenital hypothyroidism}} | ||
|width=100px|{{#pwImage:Pathway:WP4298|250px||Viral Acute Myocarditis (Homo sapiens)}} | |width=100px|{{#pwImage:Pathway:WP4298|250px||Viral Acute Myocarditis (Homo sapiens)}} | ||
| - | |width=100px|{{#pwImage:Pathway:WP4577|250px|| | + | |width=100px|{{#pwImage:Pathway:WP4577|250px||Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway}} |
|} | |} | ||
{| style="margin: 10px" | {| style="margin: 10px" | ||
| - | |width=100px|{{#pwImage:Pathway:WP4947|250px|| | + | |width=100px|{{#pwImage:Pathway:WP4947|250px||Nitric oxide metabolism in cystic fibrosis}} |
| + | |width=100px|{{#pwImage:Pathway:WP5087|250px||Malignant pleural mesothelioma}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4804|250px||Cholesterol biosynthesis with skeletal dysplasias}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP5114|250px||Nucleotide excision repair in xeroderma pigmentosum}} | ||
|} | |} | ||
| + | |||
== Copy number variation syndromes == | == Copy number variation syndromes == | ||
{| style="margin: 10px" | {| style="margin: 10px" | ||
|width=100px|{{#pwImage:Pathway:WP4905|250px||1q21.1 copy number variation syndrome}} | |width=100px|{{#pwImage:Pathway:WP4905|250px||1q21.1 copy number variation syndrome}} | ||
|width=100px|{{#pwImage:Pathway:WP4906|250px||3q29 copy number variation syndrome}} | |width=100px|{{#pwImage:Pathway:WP4906|250px||3q29 copy number variation syndrome}} | ||
| - | |width=100px|{{#pwImage:Pathway:WP4657|250px||22q11.2 | + | |width=100px|{{#pwImage:Pathway:WP4657|250px||22q11.2 copy number variation syndrome}} |
|width=100px|{{#pwImage:Pathway:WP3998|250px||Prader-Willi and Angelman Syndrome}} | |width=100px|{{#pwImage:Pathway:WP3998|250px||Prader-Willi and Angelman Syndrome}} | ||
|} | |} | ||
{| style="margin: 10px" | {| style="margin: 10px" | ||
| - | |width=100px|{{#pwImage:Pathway:WP4932|250px|| | + | |width=100px|{{#pwImage:Pathway:WP4932|250px||7q11.23 copy number variation syndrome}} |
|width=100px|{{#pwImage:Pathway:WP4940|250px||15q11.2 copy number variation syndrome}} | |width=100px|{{#pwImage:Pathway:WP4940|250px||15q11.2 copy number variation syndrome}} | ||
|width=100px|{{#pwImage:Pathway:WP4942|250px||15q13.3 copy number variation syndrome}} | |width=100px|{{#pwImage:Pathway:WP4942|250px||15q13.3 copy number variation syndrome}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4949|250px||16p11.2 proximal deletion syndrome}} | ||
|} | |} | ||
| + | {| style="margin: 10px" | ||
| + | |width=100px|{{#pwImage:Pathway:WP4950|250px||16p11.2 distal deletion syndrome}} | ||
| + | |} | ||
| + | |||
== Laminopathies == | == Laminopathies == | ||
{| style="margin: 10px" | {| style="margin: 10px" | ||
| Line 49: | Line 58: | ||
|width=100px|{{#pwImage:Pathway:WP4535|250px||Envelope proteins and their potential roles in EDMD physiopathology}} | |width=100px|{{#pwImage:Pathway:WP4535|250px||Envelope proteins and their potential roles in EDMD physiopathology}} | ||
|} | |} | ||
| + | |||
| + | == Disorders of sex development == | ||
| + | {| style="margin: 10px" | ||
| + | |width=100px|{{#pwImage:Pathway:WP4673|250px||Genes involved in male infertility}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4871|250px||Kisspeptin/Kisspeptin Receptor System in the Ovary}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4842|250px||Mammalian disorder of sexual development}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4835|250px||Peroxiredoxin 2 induced ovarian failure}} | ||
| + | |} | ||
| + | {| style="margin: 10px" | ||
| + | |width=100px|{{#pwImage:Pathway:WP4814|250px||Somatic Sex determination}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4524|250px||The alternative pathway of fetal androgen synthesis}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP5074|250px||Kallmann syndrome}} | ||
| + | |} | ||
| + | == CAKUT (congenital anomalies of the kidney and urinary tract)== | ||
| + | {| style="margin: 10px" | ||
| + | |width=100px|{{#pwImage:Pathway:WP5053|250px||Development of uretric collection system}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4830|250px||GDNF/RET signalling axis}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4823|250px||Genes controlling renal nephrogenesis}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP5052|250px||Nephrogenesis}} | ||
| + | |} | ||
| + | |||
| + | == Lipodystrophy, dyslipidemia and hyperlipidemia == | ||
| + | {| style="margin: 10px" | ||
| + | |width=100px|{{#pwImage:Pathway:WP5105|250px||Meta pathway lipodystrophy, dyslipidemia and hyperlipidemia}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP5108|250px||Familial hyperlipidemia type 1}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP5109|250px||Familial hyperlipidemia type 2}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP5110|250px||Familial hyperlipidemia type 3}} | ||
| + | |} | ||
| + | {| style="margin: 10px" | ||
| + | |width=100px|{{#pwImage:Pathway:WP5111|250px||Familial hyperlipidemia type 4}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP5112|250px||Familial hyperlipidemia type 5}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP5104|250px||Acquired partial lipodystrophy / Barraquer-Simons syndrome}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP5103|250px||Progeria-associated lipodystrophy}} | ||
| + | |} | ||
| + | {| style="margin: 10px" | ||
| + | |width=100px|{{#pwImage:Pathway:WP5102|250px||Familial partial lipodystrophy (FPLD)}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP5101|250px||Congenital generalized lipodystrophy (CGL)}} | ||
| + | |} | ||
| + | |||
== Inborn errors of metabolism == | == Inborn errors of metabolism == | ||
{| style="margin: 10px" | {| style="margin: 10px" | ||
| Line 57: | Line 105: | ||
|} | |} | ||
{| style="margin: 10px" | {| style="margin: 10px" | ||
| - | |width=100px|{{#pwImage:Pathway:WP4292|250px|| | + | |width=100px|{{#pwImage:Pathway:WP4292|250px||Methionine metabolism leading to sulfur amino acids and related disorders}} |
|width=100px|{{#pwImage:Pathway:WP4259|250px||Disorders of Folate Metabolism and Transport}} | |width=100px|{{#pwImage:Pathway:WP4259|250px||Disorders of Folate Metabolism and Transport}} | ||
|width=100px|{{#pwImage:Pathway:WP4288|250px||MTHFR deficiency (additonal pathway)}} | |width=100px|{{#pwImage:Pathway:WP4288|250px||MTHFR deficiency (additonal pathway)}} | ||
| Line 64: | Line 112: | ||
{| style="margin: 10px" | {| style="margin: 10px" | ||
|width=100px|{{#pwImage:Pathway:WP4236|250px||Disorders of the Krebs Cycle}} | |width=100px|{{#pwImage:Pathway:WP4236|250px||Disorders of the Krebs Cycle}} | ||
| - | |width=100px|{{#pwImage:Pathway:WP4153|250px|| | + | |width=100px|{{#pwImage:Pathway:WP4153|250px||Degradation pathway of sphingolipids, including diseases}} |
|width=100px|{{#pwImage:Pathway:WP4220|250px||Neurotransmitter Disorders}} | |width=100px|{{#pwImage:Pathway:WP4220|250px||Neurotransmitter Disorders}} | ||
|width=100px|{{#pwImage:Pathway:WP4224|250px||Purine Disorders}} | |width=100px|{{#pwImage:Pathway:WP4224|250px||Purine Disorders}} | ||
| Line 83: | Line 131: | ||
|width=100px|{{#pwImage:Pathway:WP4792|250px||Purine metabolism}} | |width=100px|{{#pwImage:Pathway:WP4792|250px||Purine metabolism}} | ||
|width=100px|{{#pwImage:Pathway:WP4545|250px||Oxysterols derived from cholesterol}} | |width=100px|{{#pwImage:Pathway:WP4545|250px||Oxysterols derived from cholesterol}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4595|250px||Urea cycle and associated pathways}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP5029|250px||Amino acid transport defects}} | ||
|} | |} | ||
| - | |||
{| style="margin: 10px" | {| style="margin: 10px" | ||
| - | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP4686|250px||Leucine, isoleucine and valine metabolism}} |
| - | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP5028|250px||Glycine metabolism, including IEMs}} |
| - | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP4157|250px||GABA metabolism (aka GHB)}} |
| - | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP5026|250px||Proline and hydroxyproline pathways}} |
|} | |} | ||
{| style="margin: 10px" | {| style="margin: 10px" | ||
| - | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP4686|250px||Leucine, isoleucine and valine metabolism}} |
| - | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP5028|250px||Glycine metabolism, including IEMs}} |
| + | |width=100px|{{#pwImage:Pathway:WP4157|250px||GABA metabolism (aka GHB)}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP5026|250px||Proline and hydroxyproline pathways}} | ||
|} | |} | ||
| - | |||
{| style="margin: 10px" | {| style="margin: 10px" | ||
| - | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP4688|250px||Serine metabolism}} |
| - | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP5031|250px||Biotin metabolism, including IEMs}} |
| - | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP5037|250px||Riboflavin and CoQ disorders}} |
| - | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP4971|250px||Phosphoinositides metabolism}} |
| + | |} | ||
| + | {| style="margin: 10px" | ||
| + | |width=100px|{{#pwImage:Pathway:WP5030|250px||Ethylmalonic encephalopathy}} | ||
|} | |} | ||
| Line 112: | Line 165: | ||
* [[Pathway:WP3995]] - Prion disease pathway | * [[Pathway:WP3995]] - Prion disease pathway | ||
* [[Pathway:WP3998]] - Prader-Willi and Angelman Syndrome | * [[Pathway:WP3998]] - Prader-Willi and Angelman Syndrome | ||
| - | * [[Pathway:WP4153]] - | + | * [[Pathway:WP4153]] - Degradation pathway of sphingolipids, including diseases |
* [[Pathway:WP4156]] - Disorders of Phenylalanine and Tetrahydrobiopterin | * [[Pathway:WP4156]] - Disorders of Phenylalanine and Tetrahydrobiopterin | ||
| + | * [[Pathway:WP4157]] - GABA metabolism (aka GHB) | ||
* [[Pathway:WP4220]] - Neurotransmitter Disorders | * [[Pathway:WP4220]] - Neurotransmitter Disorders | ||
* [[Pathway:WP4224]] - Purine Disorders | * [[Pathway:WP4224]] - Purine Disorders | ||
| Line 122: | Line 176: | ||
* [[Pathway:WP4271]] - Vitamin B12 Disorders | * [[Pathway:WP4271]] - Vitamin B12 Disorders | ||
* [[Pathway:WP4288]] - MTHFR deficiency | * [[Pathway:WP4288]] - MTHFR deficiency | ||
| - | * [[Pathway:WP4292]] - | + | * [[Pathway:WP4292]] - Methionine metabolism leading to sulfur amino acids and related disorders |
* [[Pathway:WP4297]] - Thiamine Disorders | * [[Pathway:WP4297]] - Thiamine Disorders | ||
* [[Pathway:WP4298]] - Viral Acute Myocarditis | * [[Pathway:WP4298]] - Viral Acute Myocarditis | ||
| Line 142: | Line 196: | ||
* [[Pathway:WP4545]] - Oxysterols derived from cholesterol | * [[Pathway:WP4545]] - Oxysterols derived from cholesterol | ||
* [[Pathway:WP4549]] - Fragile X Syndrome | * [[Pathway:WP4549]] - Fragile X Syndrome | ||
| - | * [[Pathway:WP4577]] - | + | * [[Pathway:WP4577]] - Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway |
| + | * [[Pathway:WP4595]] - Urea cycle and associated pathways | ||
* [[Pathway:WP4656]] - Joubert Syndrome | * [[Pathway:WP4656]] - Joubert Syndrome | ||
* [[Pathway:WP4657]] - 22q11.2 Deletion Syndrome | * [[Pathway:WP4657]] - 22q11.2 Deletion Syndrome | ||
* [[Pathway:WP4673]] - Genes involved in male infertility | * [[Pathway:WP4673]] - Genes involved in male infertility | ||
| + | * [[Pathway:WP4686]] - Leucine, isoleucine and valine metabolism | ||
| + | * [[Pathway:WP4688]] - Serine metabolism | ||
* [[Pathway:WP4746]] - Thyroid hormones production and their peripheral downstream signalling effects regarding congenital hypothyroidism | * [[Pathway:WP4746]] - Thyroid hormones production and their peripheral downstream signalling effects regarding congenital hypothyroidism | ||
* [[Pathway:WP4792]] - Purine metabolism | * [[Pathway:WP4792]] - Purine metabolism | ||
| + | * [[Pathway:WP4803]] - Ciliopathies | ||
| + | * [[Pathway:WP4804]] - Cholesterol biosynthesis with skeletal dysplasias | ||
* [[Pathway:WP4814]] - Somatic Sex determination | * [[Pathway:WP4814]] - Somatic Sex determination | ||
| - | |||
* [[Pathway:WP4823]] - Genes controlling renal nephrogenesis | * [[Pathway:WP4823]] - Genes controlling renal nephrogenesis | ||
* [[Pathway:WP4830]] - GDNF/RET signalling axis | * [[Pathway:WP4830]] - GDNF/RET signalling axis | ||
* [[Pathway:WP4835]] - Peroxiredoxin 2 induced ovarian failure | * [[Pathway:WP4835]] - Peroxiredoxin 2 induced ovarian failure | ||
| - | |||
* [[Pathway:WP4842]] - Mammalian disorder of sexual development | * [[Pathway:WP4842]] - Mammalian disorder of sexual development | ||
* [[Pathway:WP4844]] - The influence of laminopathies on Wnt signaling | * [[Pathway:WP4844]] - The influence of laminopathies on Wnt signaling | ||
| Line 160: | Line 217: | ||
* [[Pathway:WP4905]] - 1q21.1 copy number variation syndrome | * [[Pathway:WP4905]] - 1q21.1 copy number variation syndrome | ||
* [[Pathway:WP4906]] - 3q29 copy number variation syndrome | * [[Pathway:WP4906]] - 3q29 copy number variation syndrome | ||
| - | + | * [[Pathway:WP4932]] - 7q11.23 copy number variation syndrome | |
| - | * [[Pathway:WP4932]] - | + | |
* [[Pathway:WP4940]] - 15q11.2 copy number variation syndrome | * [[Pathway:WP4940]] - 15q11.2 copy number variation syndrome | ||
| + | * [[Pathway:WP4942]] - 15q13.3 copy number variation syndrome | ||
| + | * [[Pathway:WP4947]] - Nitric oxide metabolism in cystic fibrosis | ||
| + | * [[Pathway:WP4949]] - 16p11.2 proximal deletion syndrome | ||
| + | * [[Pathway:WP4950]] - 16p11.2 distal deletion syndrome | ||
| + | * [[Pathway:WP4971]] - Phosphoinositides metabolism | ||
| + | * [[Pathway:WP5026]] - Proline and hydroxyproline pathways | ||
| + | * [[Pathway:WP5028]] - Glycine metabolism, including IEMs | ||
| + | * [[Pathway:WP5029]] - Amino acid transport defects | ||
| + | * [[Pathway:WP5030]] - Ethylmalonic encephalopathy | ||
| + | * [[Pathway:WP5031]] - Biotin metabolism, including IEMs | ||
| + | * [[Pathway:WP5037]] - Riboflavin and CoQ disorders | ||
| + | * [[Pathway:WP5052]] - Nephrogenesis | ||
| + | * [[Pathway:WP5053]] - Development of uretric collection system | ||
| + | * [[Pathway:WP5074]] - Kallmann syndrome | ||
| + | * [[Pathway:WP5087]] - Malignant pleural mesothelioma | ||
| + | * [[Pathway:WP5101]] - Congenital generalized lipodystrophy (CGL) | ||
| + | * [[Pathway:WP5102]] - Familial partial lipodystrophy (FPLD) | ||
| + | * [[Pathway:WP5103]] - Progeria-associated lipodystrophy | ||
| + | * [[Pathway:WP5104]] - Acquired partial lipodystrophy / Barraquer-Simons syndrome | ||
| + | * [[Pathway:WP5105]] - Meta pathway lipodystrophy, dyslipidemia and hyperlipidemia | ||
| + | * [[Pathway:WP5108]] - Familial hyperlipidemia type 1 | ||
| + | * [[Pathway:WP5109]] - Familial hyperlipidemia type 2 | ||
| + | * [[Pathway:WP5110]] - Familial hyperlipidemia type 3 | ||
| + | * [[Pathway:WP5111]] - Familial hyperlipidemia type 4 | ||
| + | * [[Pathway:WP5112]] - Familial hyperlipidemia type 5 | ||
| + | * [[Pathway:WP5114]] - Nucleotide excision repair in xeroderma pigmentosum | ||
Current revision
Contents |
Rare diseases in general
|
Image does not exist Alzheimers Disease |
Image does not exist Amyotrophic lateral sclerosis (ALS) (Homo sapiens) |
Image does not exist ERK Pathway in Huntington's Disease |
Image does not exist Ciliopathies |
|
Image does not exist Fanconi Anemia Pathway (Homo sapiens) |
Image does not exist Fragile X Syndrome |
Image does not exist Joubert Syndrome |
Image does not exist MECP2 and Associated Rett Syndrome (Homo sapiens) |
|
Image does not exist Pathways Regulating Hippo Signaling |
Image does not exist Parkinsons Disease Pathway |
Image does not exist po-Merlin Signaling Dysregulation |
Image does not exist Prion disease pathway |
|
Image does not exist Rett syndrome causing genes |
Image does not exist Thyroid hormones production and their peripheral downstream signalling effects regarding congenital hypothyroidism |
Image does not exist Viral Acute Myocarditis (Homo sapiens) |
Image does not exist Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway |
|
Image does not exist Nitric oxide metabolism in cystic fibrosis |
Image does not exist Malignant pleural mesothelioma |
Image does not exist Cholesterol biosynthesis with skeletal dysplasias |
Image does not exist Nucleotide excision repair in xeroderma pigmentosum |
Copy number variation syndromes
|
Image does not exist 1q21.1 copy number variation syndrome |
Image does not exist 3q29 copy number variation syndrome |
Image does not exist 22q11.2 copy number variation syndrome |
Image does not exist Prader-Willi and Angelman Syndrome |
|
Image does not exist 7q11.23 copy number variation syndrome |
Image does not exist 15q11.2 copy number variation syndrome |
Image does not exist 15q13.3 copy number variation syndrome |
Image does not exist 16p11.2 proximal deletion syndrome |
|
Image does not exist 16p11.2 distal deletion syndrome |
Laminopathies
|
Image does not exist Interacting Laminopathic Pathways |
Image does not exist Lamin A-processing pathway (Homo sapiens) |
Image does not exist The effect of progerin on the involved genes in Hutchinson-Gilford Progeria Syndrome (Homo sapiens) |
Image does not exist The influence of laminopathies on Wnt signaling |
|
Image does not exist Envelope proteins and their potential roles in EDMD physiopathology |
Disorders of sex development
|
Image does not exist Genes involved in male infertility |
Image does not exist Kisspeptin/Kisspeptin Receptor System in the Ovary |
Image does not exist Mammalian disorder of sexual development |
Image does not exist Peroxiredoxin 2 induced ovarian failure |
|
Image does not exist Somatic Sex determination |
Image does not exist The alternative pathway of fetal androgen synthesis |
Image does not exist Kallmann syndrome |
CAKUT (congenital anomalies of the kidney and urinary tract)
|
Image does not exist Development of uretric collection system |
Image does not exist GDNF/RET signalling axis |
Image does not exist Genes controlling renal nephrogenesis |
Image does not exist Nephrogenesis |
Lipodystrophy, dyslipidemia and hyperlipidemia
|
Image does not exist Meta pathway lipodystrophy, dyslipidemia and hyperlipidemia |
Image does not exist Familial hyperlipidemia type 1 |
Image does not exist Familial hyperlipidemia type 2 |
Image does not exist Familial hyperlipidemia type 3 |
|
Image does not exist Familial hyperlipidemia type 4 |
Image does not exist Familial hyperlipidemia type 5 |
Image does not exist Acquired partial lipodystrophy / Barraquer-Simons syndrome |
Image does not exist Progeria-associated lipodystrophy |
|
Image does not exist Familial partial lipodystrophy (FPLD) |
Image does not exist Congenital generalized lipodystrophy (CGL) |
Inborn errors of metabolism
|
Image does not exist Molybdenum (Moco) cofactor biosynthesis |
Image does not exist Cysteine and Methionine catabolism |
Image does not exist Vitamin B12 Disorders |
Image does not exist Thiamine Disorders |
|
Image does not exist Methionine metabolism leading to sulfur amino acids and related disorders |
Image does not exist Disorders of Folate Metabolism and Transport |
Image does not exist MTHFR deficiency (additonal pathway) |
Image does not exist Vitamine B6-Dependent and Responsive Disorders |
|
Image does not exist Disorders of the Krebs Cycle |
Image does not exist Degradation pathway of sphingolipids, including diseases |
Image does not exist Neurotransmitter Disorders |
Image does not exist Purine Disorders |
|
Image does not exist Pyrimidine Disorders |
Image does not exist Disorders of Phenylalanine and Tetrahydrobiopterin (BH4) Metabolism |
Image does not exist Tyrosine Metabolism |
Image does not exist Gamma-Glutamyl Cycle for the biosynthesis and degradation of glutathione, including diseases |
|
Image does not exist Cerebral Organic Acidurias |
Image does not exist Glycosylation and related congenital defects |
Image does not exist Metabolic pathway of LDL, HDL and TG |
Image does not exist Classical pathway of steroidogenesis, including diseases |
|
Image does not exist Purine metabolism |
Image does not exist Oxysterols derived from cholesterol |
Image does not exist Urea cycle and associated pathways |
Image does not exist Amino acid transport defects |
|
Image does not exist Leucine, isoleucine and valine metabolism |
Image does not exist Glycine metabolism, including IEMs |
Image does not exist GABA metabolism (aka GHB) |
Image does not exist Proline and hydroxyproline pathways |
|
Image does not exist Leucine, isoleucine and valine metabolism |
Image does not exist Glycine metabolism, including IEMs |
Image does not exist GABA metabolism (aka GHB) |
Image does not exist Proline and hydroxyproline pathways |
|
Image does not exist Serine metabolism |
Image does not exist Biotin metabolism, including IEMs |
Image does not exist Riboflavin and CoQ disorders |
Image does not exist Phosphoinositides metabolism |
|
Image does not exist Ethylmalonic encephalopathy |
List of featured pathways:
- Pathway:WP2059 - Alzheimers Disease
- Pathway:WP2371 - Parkinsons Disease Pathway
- Pathway:WP2447 - Amyotrophic lateral sclerosis (ALS)
- Pathway:WP3569 - Fanconi Anemia Pathway
- Pathway:WP3584 - MECP2 and Associated Rett Syndrome
- Pathway:WP3853 - ERK Pathway in Huntington's Disease
- Pathway:WP3995 - Prion disease pathway
- Pathway:WP3998 - Prader-Willi and Angelman Syndrome
- Pathway:WP4153 - Degradation pathway of sphingolipids, including diseases
- Pathway:WP4156 - Disorders of Phenylalanine and Tetrahydrobiopterin
- Pathway:WP4157 - GABA metabolism (aka GHB)
- Pathway:WP4220 - Neurotransmitter Disorders
- Pathway:WP4224 - Purine Disorders
- Pathway:WP4225 - Pyrimidine Disorder
- Pathway:WP4228 - Vitamine B6-Dependent and Responsive Disorders
- Pathway:WP4236 - Disorders of the Krebs Cycle
- Pathway:WP4259 - Disorders of Folate Metabolism and Transport
- Pathway:WP4271 - Vitamin B12 Disorders
- Pathway:WP4288 - MTHFR deficiency
- Pathway:WP4292 - Methionine metabolism leading to sulfur amino acids and related disorders
- Pathway:WP4297 - Thiamine Disorders
- Pathway:WP4298 - Viral Acute Myocarditis
- Pathway:WP4299 - Lamin A-processing pathway
- Pathway:WP4312 - Rett syndrome causing genes
- Pathway:WP4320 - The effect of progerin on the involved genes in Hutchinson-Gilford Progeria Syndrome
- Pathway:WP4504 - Cysteine and Methionine catabolism
- Pathway:WP4506 - Tyrosine Metabolism
- Pathway:WP4507 - Molybdenum (Moco) cofactor biosynthesis
- Pathway:WP4518 - Gamma-Glutamyl Cycle for the biosynthesis and degradation of glutathione, including diseases
- Pathway:WP4519 - Cerebral Organic Acidurias
- Pathway:WP4521 - Glycosylation and related congenital defects
- Pathway:WP4522 - Metabolic pathway of LDL, HDL and TG
- Pathway:WP4523 - Classical pathway of steroidogenesis, including diseases
- Pathway:WP4524 - The alternative pathway of fetal androgen synthesis
- Pathway:WP4535 - Envelope proteins and their potential roles in EDMD physiopathology
- Pathway:WP4540 - Pathways Regulating Hippo Signaling
- Pathway:WP4541 - po-Merlin Signaling Dysregulation
- Pathway:WP4545 - Oxysterols derived from cholesterol
- Pathway:WP4549 - Fragile X Syndrome
- Pathway:WP4577 - Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway
- Pathway:WP4595 - Urea cycle and associated pathways
- Pathway:WP4656 - Joubert Syndrome
- Pathway:WP4657 - 22q11.2 Deletion Syndrome
- Pathway:WP4673 - Genes involved in male infertility
- Pathway:WP4686 - Leucine, isoleucine and valine metabolism
- Pathway:WP4688 - Serine metabolism
- Pathway:WP4746 - Thyroid hormones production and their peripheral downstream signalling effects regarding congenital hypothyroidism
- Pathway:WP4792 - Purine metabolism
- Pathway:WP4803 - Ciliopathies
- Pathway:WP4804 - Cholesterol biosynthesis with skeletal dysplasias
- Pathway:WP4814 - Somatic Sex determination
- Pathway:WP4823 - Genes controlling renal nephrogenesis
- Pathway:WP4830 - GDNF/RET signalling axis
- Pathway:WP4835 - Peroxiredoxin 2 induced ovarian failure
- Pathway:WP4842 - Mammalian disorder of sexual development
- Pathway:WP4844 - The influence of laminopathies on Wnt signaling
- Pathway:WP4871 - Kisspeptin/Kisspeptin Receptor System in the Ovary
- Pathway:WP4879 - Interacting Laminopathic Pathways
- Pathway:WP4905 - 1q21.1 copy number variation syndrome
- Pathway:WP4906 - 3q29 copy number variation syndrome
- Pathway:WP4932 - 7q11.23 copy number variation syndrome
- Pathway:WP4940 - 15q11.2 copy number variation syndrome
- Pathway:WP4942 - 15q13.3 copy number variation syndrome
- Pathway:WP4947 - Nitric oxide metabolism in cystic fibrosis
- Pathway:WP4949 - 16p11.2 proximal deletion syndrome
- Pathway:WP4950 - 16p11.2 distal deletion syndrome
- Pathway:WP4971 - Phosphoinositides metabolism
- Pathway:WP5026 - Proline and hydroxyproline pathways
- Pathway:WP5028 - Glycine metabolism, including IEMs
- Pathway:WP5029 - Amino acid transport defects
- Pathway:WP5030 - Ethylmalonic encephalopathy
- Pathway:WP5031 - Biotin metabolism, including IEMs
- Pathway:WP5037 - Riboflavin and CoQ disorders
- Pathway:WP5052 - Nephrogenesis
- Pathway:WP5053 - Development of uretric collection system
- Pathway:WP5074 - Kallmann syndrome
- Pathway:WP5087 - Malignant pleural mesothelioma
- Pathway:WP5101 - Congenital generalized lipodystrophy (CGL)
- Pathway:WP5102 - Familial partial lipodystrophy (FPLD)
- Pathway:WP5103 - Progeria-associated lipodystrophy
- Pathway:WP5104 - Acquired partial lipodystrophy / Barraquer-Simons syndrome
- Pathway:WP5105 - Meta pathway lipodystrophy, dyslipidemia and hyperlipidemia
- Pathway:WP5108 - Familial hyperlipidemia type 1
- Pathway:WP5109 - Familial hyperlipidemia type 2
- Pathway:WP5110 - Familial hyperlipidemia type 3
- Pathway:WP5111 - Familial hyperlipidemia type 4
- Pathway:WP5112 - Familial hyperlipidemia type 5
- Pathway:WP5114 - Nucleotide excision repair in xeroderma pigmentosum
